Clinical Trials Logo

Thymic Epithelial Tumor clinical trials

View clinical trials related to Thymic Epithelial Tumor.

Filter by:

NCT ID: NCT03858582 Recruiting - Clinical trials for Thymic Epithelial Tumor

neoadjuvant_thymic Epithelial Tumor

Start date: April 29, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase II single center, open-label, single arm study in patients with unresectable thymic epithelial tumors (Masaoka stage III, IVA). Patients will be treated with Pembrolizumab 200 mg, Docetaxel 75mg/m2, Cisplatin 75mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles. Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles. Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles. Otherwise patients are off the study.

NCT ID: NCT03212027 Not yet recruiting - Clinical trials for Thymic Epithelial Tumor

Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging

Start date: July 31, 2017
Phase: N/A
Study type: Observational

The aim of this study is to analyze aquaporins expression of thymic epithelial tumors and to compare them with apparent diffusion coefficient(ADC) from ultra-high b-values, and to test a possibility of use of ADCuh to identify the pathological type of tumor.

NCT ID: NCT02724696 Recruiting - Clinical trials for Thymic Epithelial Tumor

French National Observatory of Patients With Thymic Epithelial Tumor

RYTHMIC
Start date: January 2012
Phase:
Study type: Observational

RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French nationwide network for TET with the objective of territorial coverage by regional expert centers and systematic discussion of patients management at national tumor board.